A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
Clinical trial NCT05650385 · UNKNOWN
Trial details
- NCT number
- NCT05650385
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2023-12-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.